Table 5 .
Case No |
Age | Gender | Manual RPR |
Automated RPR (RU) |
TPPA | Pretreatment VDRL test value |
Time after initial treatment (days) | Initial treatment | Diagnosis |
---|---|---|---|---|---|---|---|---|---|
1 | 54 | Male | 2+ | 0 | 1:5120 | 1:8 reactive | 939 | Penicillin G benzathine 1.2×106 IU | Syphilis, latent |
2 | 66 | Male | 0.5+ | 0 | 1:640 | 1:1 weakly reactive | 903 | Penicillin G benzathine 1.2×106 IU | Treated syphilis |
3 | 17 | Male | 2+ | 0 | 1:5120 | 1:4 reactive | 222 | Penicillin G benzathine 1.2×106 IU | Syphilis, late, latent |
4 | 62 | Male | 2+ | 0 | 1:640 | 1:1 reactive | 296 | Penicillin G benzathine 1.2×106 IU | Syphilis, other and unspecified |
5 | 68 | Male | 1+ | 0 | 1:320 | 1:1 weakly reactive | 644 | Penicillin G benzathine 1.2×106 IU | Syphilis, late, latent |
6 | 72 | Male | 1+ | 0 | 1:640 | 1:1 weakly reactive | 28 | Penicillin G benzathine 1.2×106 IU | Syphilis, late, unspecified |
7 | 55 | Female | 0 | 0 | 1:1280 | N/A | 0 | Penicillin G benzathine 1.2×106 IU | Syphilis, latent |
8 | 56 | Female | 1+ | 0 | 1:5120 | 1:1 weakly reactive | 7 | Penicillin G benzathine 1.2×106 IU | Syphilis, latent |
9 | 65 | Female | 2+ | 0 | 1:80 | 1:1 reactive | 0 | Penicillin G benzathine 1.2×106 IU | Syphilis, late |
10 | 33 | Female | 1+ | 0 | 1:5120 | 1:8 reactive | 936 | Penicillin G benzathine 1.2×106 IU | Syphilis, other and unspecified |
11 | 28 | Female | 2+ | 1 | 1:2560 | 1:1 reactive | 1097 | Penicillin G benzathine 1.2×106 IU | Syphilis, late, latent |
12 | 2 | Male | 2+ | 1.1 | 1:5120 | 1:32 reactive | 539 | Penicillin G benzathine 1.2×106 IU | Syphilis, congenital, latent |
13 | 65 | Male | 3+ | 1.3 | 1:640 | 1:1 reactive | 273 | Penicillin G Benzathine 1.2×106 IU | Treated syphilis |
14 | 70 | Male | 3+ | 2.3 | 1:1280 | 1:1 reactive | 188 | Doxycycline 100 mg | Syphilis, late, latent |
15 | 48 | Female | 2+ | 2.5 | 1:5120 | 1:1 weakly reactive | 665 | Penicillin G benzathine 1.2×106 IU | Treated syphilis |
16 | 36 | Female | 2+ | 3.8 | 1:5120 | 1:2 reactive | 810 | Penicillin G benzathine 1.2×106 IU | Syphilis, latent |
17 | 74 | Female | 4+ | 7.7 | 1:320 | 1:4 reactive | 669 | Penicillin G benzathine 1.2×106 IU | Syphilis, late, latent |
18 | 25 | Female | 4+ | 8.1 | 1:5120 | 1:8 reactive | 172 | Penicillin G benzathine 1.2×106 IU | Syphilis with pregnancy |
19 | 64 | Female | 4+ | 14.1 | 1:5120 | 1:8 reactive | 0 | Penicillin G benzathine 1.2×106 IU | Chronic rhinitis |
20 | 30 | Male | 4+ | 20 | 1:2560 | 1:16 reactive | 7 | Penicillin G benzathine 1.2×106 IU | Syphilis, late, unspecified |
21 | 31 | Female | 2+ | 20 | 1:5120 | 1:16 reactive | 3 | Penicillin G benzathine 1.2×106 IU | Syphilis with pregnancy |
22 | 51 | Female | 4+ | 20.4 | 1:5120 | 1:8 reactive | 417 | Penicillin G benzathine 1.2×106 IU | Syphilis, latent |
23 | 37 | Female | 2+ | 25.6 | 1:5120 | 1:16 reactive | 0 | Penicillin G benzathine 1.2×106 IU | Treated syphilis |
N/A, not applicable; RPR, rapid plasma reagin; RU, RPR unit; TPPA, Treponema pallidum particle agglutination; VDRL, Venereal Disease Research Laboratory.